{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:36:23Z","timestamp":1785198983007,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nowadays, in the study of rheumatoid arthritis (RA), more and more interest is directed towards an earlier effective therapeutic intervention and the determination of companion markers for predicting response to therapy with the goal to prevent progressive joint damage, deformities, and functional disability. With the present work, we aimed at quantifying in a cohort of early RA (ERA) patients na\u00efve to DMARD therapy, proteins whose increase was previously found associated with RA: serum amyloid A (A-SAA) and alarmins. Five A-SAA variants (SAA1\u03b1, SAA1\u03b2, SAA1\u03b3, SAA2\u03b1, and SAA2\u03b2) but also S100A8 and S100A9 proteins were simultaneously quantified in plasma applying a method based on single targeted bottom-up proteomics LC-MS\/MS. First, we compared their expression between ERA (n = 100) and healthy subjects (n = 100), then we focused on their trend by monitoring ERA patients na\u00efve to DMARD treatment, 1 year after starting therapy. Only SAA1\u03b1 and SAA2\u03b1 levels were increased in ERA patients, and SAA2\u03b1 appears to mostly mediate the pathological role of A-SAA. Levels of these variants, together with SAA1\u03b2, only decreased under biologic DMARD treatment but not under methotrexate monotherapy. This study highlights the importance to better understand the modulation of expression of these variants in ERA in order to subsequently better characterize their biological function. On the other hand, alarmin expression increased in ERA compared to controls but remained elevated after 12 months of methotrexate or biologic treatment. The work overcomes the concept of considering these proteins as biomarkers for diagnosis, demonstrating that SAA1\u03b1, SAA1\u03b2, and SAA2\u03b1 variants but also S100A8 and S100A9 do not respond to all early treatment in ERA and should be rather considered as companion markers useful to improve the follow-up of treatment response and remission state. Moreover, it suggests that earlier use of biologics in addition to methotrexate may be worth considering.<\/jats:p>","DOI":"10.3389\/fimmu.2021.638814","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:01:20Z","timestamp":1629453680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid Arthritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Federica","family":"Ciregia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Nys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Cobraiville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Badot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Di Romana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Sidiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Fillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G.","family":"Malaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"de Seny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid Arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis, A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in Patients With Rheumatoid Arthritis: A 15-Year Prospective Cohort Study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheumatol Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.10.002","article-title":"Update of French Society for Rheumatology Recommendations for Managing Rheumatoid Arthritis","volume":"86","author":"Daien","year":"2019","journal-title":"Joint Bone Spine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/art.27692","article-title":"Long-Term Impact of Delay in Assessment of Patients With Early Arthritis","volume":"62","author":"van der Linden","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez049","article-title":"Validity of a Two-Component Imaging-Derived Disease Activity Score for Improved Assessment of Synovitis in Early Rheumatoid Arthritis","volume":"58","author":"Hensor","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2019.1697679","article-title":"Time to Modify the DAS28 to Make it Fit for Purpose(s) in Rheumatoid Arthritis","volume":"16","author":"Hensor","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057497","article-title":"Radiological Damage in Patients With Rheumatoid Arthritis on Sustained Remission","volume":"66","author":"Cohen","year":"2007","journal-title":"Ann Rheumatol Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.099549","article-title":"Monomeric Calgranulins Measured by SELDI-TOF Mass Spectrometry and Calprotectin Measured by ELISA as Biomarkers in Arthritis","volume":"54","author":"de Seny","year":"2008","journal-title":"Clin Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5967816","article-title":"Serum Amyloid A Protein as a Potential Biomarker for Severity and Acute Outcome in Traumatic Brain Injury","volume":"2019","author":"Wicker","year":"2019","journal-title":"Biomed Res Int"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/postgradmedj-2018-136004","article-title":"Association Between Serum Amyloid A Levels and Cancers: A Systematic Review and Meta-Analysis","volume":"94","author":"Zhou","year":"2018","journal-title":"Postgrad Med J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/infdis\/146.3.443","article-title":"Serum Amyloid A Levels in Patients With Infections Due to Cytomegalovirus, Varicella-Zoster Virus, and Herpes Simplex Virus","volume":"146","author":"Sarov","year":"1982","journal-title":"J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cytogfr.2019.10.006","article-title":"Cytokines and Serum Amyloid A in the Pathogenesis of Hepatitis C Virus Infection","volume":"50","author":"Abouelasrar Salama","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2804","article-title":"Increased Serum Amyloid A and Its Association With Autoantibodies, Acute Phase Reactants and Disease Activity in Patients With Rheumatoid Arthritis","volume":"11","author":"Shen","year":"2015","journal-title":"Mol Med Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13075-016-1009-y","article-title":"Differential Response of Serum Amyloid A to Different Therapies in Early Rheumatoid Arthritis and Its Potential Value as a Disease Activity Biomarker","volume":"18","author":"Hwang","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160418114600","article-title":"Structure and Expression of Different Serum Amyloid A (SAA) Variants and Their Concentration-Dependent Functions During Host Insults","volume":"23","author":"De Buck","year":"2016","journal-title":"Curr Med Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.631299","article-title":"Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker","volume":"11","author":"Sori\u0107 Hosman","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)00045-7","article-title":"Induction of Human Mammary-Associated Serum Amyloid A3 Expression by Prolactin or Lipopolysaccharide","volume":"301","author":"Larson","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800503","article-title":"Bacterial Lipoproteins Constitute the TLR2-Stimulating Activity of Serum Amyloid A","volume":"201","author":"Burgess","year":"2018","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13295","article-title":"The Turning Away of Serum Amyloid A Biological Activities and Receptor Usage","volume":"163","author":"Abouelasrar Salama","year":"2021","journal-title":"Immunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.27440","article-title":"The Proinflammatory Activity of Recombinant Serum Amyloid A Is Not Shared by the Endogenous Protein in the Circulation","volume":"62","author":"Bj\u00f6rkman","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00092","article-title":"Endogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils Through Different Receptors","volume":"4","author":"Christenson","year":"2013","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.12.008","article-title":"Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease","volume":"183","author":"Lee","year":"2020","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0698-1","article-title":"Serum Amyloid A Is a Soluble Pattern Recognition Receptor That Drives Type 2 Immunity","volume":"21","author":"Smole","year":"2020","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00843","article-title":"Serum Amyloid A1 (SAA1) Revisited: Restricted Leukocyte-Activating Properties of Homogeneous SAA1","volume":"11","author":"Abouelasrar Salama","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201400382","article-title":"Quantification of SAA1 and SAA2 in Lung Cancer Plasma Using the Isotype-Specific PRM Assays","volume":"15","author":"Kim","year":"2015","journal-title":"Proteomics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2019.06.044","article-title":"Targeted Proteomics Reveals Serum Amyloid A Variants and Alarmins S100A8-S100A9 as Key Plasma Biomarkers of Rheumatoid Arthritis","volume":"204","author":"Nys","year":"2019","journal-title":"Talanta"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01298","article-title":"S100A8\/A9 in Inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1586\/17474124.2014.869476","article-title":"The Use of Fecal Calprotectin as a Biomarker in Gastrointestinal Disease","volume":"8","author":"Burri","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.170019","article-title":"Monitoring Disease Activity by Stool Analyses: From Occult Blood to Molecular Markers of Intestinal Inflammation and Damage","volume":"58","author":"Foell","year":"2009","journal-title":"Gut"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2019-0026","article-title":"The Role of Calprotectin in Rheumatoid Arthritis","volume":"7","author":"Wang","year":"2019","journal-title":"J Transl Int Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2014.29.1.12","article-title":"S100A8\/A9 as a Biomarker for Synovial Inflammation and Joint Damage in Patients With Rheumatoid Arthritis","volume":"29","author":"Kang","year":"2014","journal-title":"Korean J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"R69","DOI":"10.1186\/ar1939","article-title":"The S100A8\/A9 Heterodimer Amplifies Proinflammatory Cytokine Production by Macrophages viaa Activation of Nuclear Factor Kappa B and P38 Mitogen-Activated Protein Kinase in Rheumatoid Arthritis","volume":"8","author":"Sunahori","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/rheumatology\/kez218","article-title":"Fc-Gamma Receptors and S100A8\/A9 Cause Bone Erosion During Rheumatoid Arthritis. Do They Act as Partners in Crime","volume":"58","author":"Di Ceglie","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-018-1584-1","article-title":"Fc\u03b3 Receptor-Mediated Influx of S100A8\/A9-Producing Neutrophils as Inducer of Bone Erosion During Antigen-Induced Arthritis","volume":"20","author":"Di Ceglie","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.103739","article-title":"Calprotectin (a Major S100 Leucocyte Protein) Predicts 10-Year Radiographic Progression in Patients With Rheumatoid Arthritis","volume":"69","author":"Hammer","year":"2010","journal-title":"Ann Rheumatol Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheumatol"},{"key":"B39","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score Using 28 Joint Counts (DAS28) in the Management of Rheumatoid Arthritis","volume":"34","author":"van Riel","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B40","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"B41","article-title":"Biomarkers in Rheumatoid Arthritis, What is New","volume":"9","author":"Gavril\u0103","year":"2016","journal-title":"J Med Life"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.063834","article-title":"Disease Activity Score 28 (DAS28) Using C-Reactive Protein Underestimates Disease Activity and Overestimates EULAR Response Criteria Compared With DAS28 Using Erythrocyte Sedimentation Rate in a Large Observational Cohort of Rheumatoid Arthritis Patients in Japan","volume":"66","author":"Matsui","year":"2007","journal-title":"Ann Rheumatol Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00185","article-title":"The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis","volume":"5","author":"Orr","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2017.1419371","article-title":"Calprotectin (S100A8\/A9) Should Preferably be Measured in EDTA-Plasma; Results From a Longitudinal Study of Patients With Rheumatoid Arthritis","volume":"78","author":"Nordal","year":"2018","journal-title":"Scand J Clin Lab Invest"},{"key":"B45","first-page":"58","article-title":"Serum Amyloid A in the Assessment of Early Inflammatory Arthritis","volume":"27","author":"Cunnane","year":"2000","journal-title":"J Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.42.6.665","article-title":"Serum Amyloid-A Protein Concentration in Rheumatoid Arthritis and Its Role in Monitoring Disease Activity","volume":"42","author":"Chambers","year":"1983","journal-title":"Ann Rheumatol Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1734-1140(10)70329-7","article-title":"Influence of Long-Term Leflunomide Treatment on Serum Amyloid Concentration in Rheumatoid Arthritis Patients","volume":"62","author":"Targo\u0144ska-St\u0119pniak","year":"2010","journal-title":"Pharmacol Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/330080a0","article-title":"Two Calcium-Binding Proteins in Infiltrate Macrophages of Rheumatoid Arthritis","volume":"330","author":"Odink","year":"1987","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211695","article-title":"Calprotectin as a Marker of Inflammation in Patients With Early Rheumatoid Arthritis","volume":"76","author":"Jonsson","year":"2017","journal-title":"Ann Rheumatol Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-016-1201-0","article-title":"Calprotectin (S100A8\/A9) has the Strongest Association With Ultrasound-Detected Synovitis and Predicts Response to Biologic Treatment: Results From a Longitudinal Study of Patients With Established Rheumatoid Arthritis","volume":"19","author":"Nordal","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2013-203923","article-title":"MRP8\/14 Serum Levels as a Strong Predictor of Response to Biological Treatments in Patients With Rheumatoid Arthritis","volume":"74","author":"Choi","year":"2015","journal-title":"Ann Rheumatol Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40291-013-0016-9","article-title":"Calprotectin in Rheumatoid Arthritis: Association With Disease Activity in a Cross-Sectional and a Longitudinal Cohort","volume":"17","author":"Garc\u00eda-Arias","year":"2013","journal-title":"Mol Diagn Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1107128","article-title":"Calprotectin (S100A8\/A9) and S100A12 are Associated With Measures of Disease Activity in a Longitudinal Study of Patients With Rheumatoid Arthritis Treated With Infliximab","volume":"45","author":"Nordal","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150998","article-title":"Myeloid-Related Protein 8\/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate","volume":"43","author":"Patro","year":"2016","journal-title":"J Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064741","article-title":"Calprotectin (a Major Leucocyte Protein) is Strongly and Independently Correlated With Joint Inflammation and Damage in Rheumatoid Arthritis","volume":"66","author":"Hammer","year":"2007","journal-title":"Ann Rheumatol Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jbspin.2019.07.001","article-title":"Calprotectin Alone Is Not Sufficient to Predict Response to Methotrexate in Early ACR\/EULAR 2010 Rheumatoid Arthritis: Analysis of the ESPOIR Cohort","volume":"87","author":"Bernardy","year":"2020","journal-title":"Joint Bone Spine"},{"key":"B57","article-title":"Functional Disability in Relation to Radiological Damage and Disease Activity in Patients With Rheumatoid Arthritis in Remission","volume":"29","author":"Molenaar","year":"2002","journal-title":"J Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.638814\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T10:01:29Z","timestamp":1629453689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.638814\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2021.638814"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.638814","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"article-number":"638814"}}